Tissue microarrays: Bridging the gap between research and the clinic

Expert Review of Proteomics

Volumn 2, Issue 3, 2005, Pages 325-336

  Braunschweig, Till ^a   Chung, Joon Yong ^a,b   Hewitt, Stephen M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Inje University College of Medicine   (South Korea)

Author keywords

Cell lines; Clinical trials; High throughput; Histology; Methodologies; Pathology; Proteomics; Tissue microarray; TMA; Translational medicine; Xenograft

Indexed keywords

ASSAY; CELL LINE; CLINICAL RESEARCH; HIGH THROUGHPUT SCREENING; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFRARED SPECTROSCOPY; LASER CAPTURE MICRODISSECTION; NONHUMAN; PROGNOSIS; REVIEW; RNA TRANSLATION; TISSUE FIXATION; TISSUE MICROARRAY; TUMOR CLASSIFICATION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; CELL LINE; CLINICAL TRIALS; HUMANS; IN SITU HYBRIDIZATION; MICROARRAY ANALYSIS; MODELS, ANIMAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RESEARCH DESIGN; RNA;

EID: 20544435397     PISSN: 14789450     EISSN: None     Source Type: Journal    
DOI: 10.1586/14789450.2.3.325     Document Type: Review

References (80)

1. Nishizuka S, Chen ST, Gwadry FG et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 63(17), 5243-5250 (2003).
2. Kriete A, Hewitt SM, DeBernardi M. Automated confocal imaging and high-content screening for cytomics. In: Handbook of Biological Confocal Microscopy. Pawley JB (Ed.), Plenum Press, NY, USA (In Press).
3. Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nature Rev. Drug Discov. 2(12), 962-972 (2003). Excellent review paper including all (at that time) clinical research using tissue microarrays (TMAs).
4. Braunschweig T, Chung JY, Hewitt SM. Perspectives in tissue microarrays. Comb. Chem. High Throughput Screen. 7(6), 575-585 (2004).
5. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J Am. Soc. Nephrol. 15(7), 1677-1689 (2004).
6. Went PT, Lugli A, Meier S et al. Frequent EpCam protein expression in human carcinomas. Hum. Pathol. 35(1), 122-128 (2004).
7. Geiszt M, Lekstrom K, Brenner S et al. NAD(P)H oxidase 1, a product of differentiated colon epithelial cells, can partially replace glycoprotein 91phox in the regulated production of Superoxide by phagocytes. J. Immunol. 171(1), 299-306 (2003). In situ hybridization with radionucleotides in TMAs.
8. Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab. Invest. 55(2), 244-248 (1986).
9. Battifora H, Mehta P. The checkerboard tissue block. An improved multitissue control block. Lab. Invest. 63(5), 722-724 (1990).
10. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med. 4(7), 844-847 (1998). Initial description of TMAs.
11. Hidalgo A, Pina P, Guerrero G, Lazos M, Salcedo M. A simple method for the construction of small format tissue arrays. J. Clin. Pathol. 56(2), 144-146 (2003). Construction of TMAs without using an apparratus.
12. Meslin EM, Quaid KA. Ethical issues in the collection, storage, and research use of human biological materials. J. Lab. Clin. Med. 144(5), 229-234 (2004).
13. Anderson BD, Adamson PC, Weiner SL, McCabe MS, Smith MA. Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives. J. Clin. Oncol. 22(23), 4794-4798 (2004).
14. Hakimian R, Korn D. Ownership and use of tissue specimens for research. JAMA 292(20), 2500-2505 (2004).
15. Gillespie JW, Best CJ, Bichsel VE et al. Evaluation of non-formalin tissue fixation for molecular profiling studies. Am. J. Pathol. 160(2), 449-457 (2002). Alternative methods of tissue fixation.
16. Hewitt SM. Tissue arrays in basic cancer research. In: Proteomics in Cancer Research. Liebler DC, Petricoin III EF, Liotta LA (Eds), John Wiley & Sons, NJ, USA (In Press).
17. Fejzo MS, Slamon DJ. Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am. J. Pathol. 159(5), 1645-1650 (2001). Frozen TMA plaform.
18. Kylaniemi M, Koskinen M, Karhunen P et al. A novel frozen brain tissue array technique: immunohistochemical detection of neuronal paraneoplastic autoantibodies. Neuropathol. Appl. Neurobiol. 30(1), 39-45 (2004).
19. Miyaji T, Hewitt SM, Liotta LA, Star RA. Frozen protein arrays: a new method for arraying and detecting recombinant and native tissue proteins. Proteomics 2(11), 1489-1493 (2002).
20. Almeida A, Paul Thiery J, Magdelenat H, Radvanyi F. Gene expression analysis by real-time reverse transcription polymerase chain reaction: influence of tissue handling. Anal. Biochem. 328(2), 101-108 (2004).
21. Dennis J, Westra J, Bell A, Montgomery K, Oien K. The type and quality of paraffin wax is important when constructing tissue microarrays. Mol. Pathol. 56(5), 306 (2003).
22. Fergenbaum JH, Garcia-Closas M, Hewitt SM et al. Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol. Biomarkers Prev. 13(4), 667-672 (2004).
23. Fernandez DC, Bhargava R, Hewitt SM, Levin IW. Infrared spectroscopic imaging for histopathologic recognition. Nature Biotech. 23(4), 469-474 (2005).
24. Korabiowska M, Quentin T, Schlott T, Bauer H, Kunze E. Downregulation of Ku 70 and Ku 80 mRNA expression in transitional cell carcinomas of the urinary bladder related to tumor progression. World J. Urol. 22(6), 431-440 (2004).
25. Hewitt SM. Design, construction, and use of tissue microarrays. Methods Mol. Biol. 264, 61-72 (2004).
26. Hewitt SM. Tissue Microarrays. In: Dissecting the Molecular Anatomy of Tissue. Emmert-Buck MR, Gillespie JW, Chuaqui RF (Eds), Springer-Verlag, Germany (2005)
27. Rao J, Seligson D, Hemstreet GP. Protein expression analysis using quantitative fluorescence image analysis on tissue microarray slides. Biotechniques 32(4), 924-926 (2002).
28. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nature Med. 8(11), 1323-1327 (2002). Immunofluorescence and quantitative image analysis with TMAs.
29. Haedicke W, Popper HH, Buck CR, Zatloukal K. Automated evaluation and normalization of immunohistochemistry on tissue microarrays with a DNA microarray scanner. Biotechniques 35(1), 164-168 (2003).
30. Tan AR, Yang X, Hewitt SM et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J. Clin. Oncol. 22(15), 3080-3090 (2004).
31. Zimmerman D, Thomas R, Scicchitano M et al. Automation of nonisotopic in situ hybridization. J Histotechnol. 26(3), 181-184 (2003).
32. Yang H, Wanner IB, Roper SD, Chaudhari N. An optimized method for in situ hybridization with signal amplification that allows the detection of rare mRNAs. J. Histochem. Cytochem. 47(4), 431-446 (1999).
33. Braissant O, Wahli W. Differential expression of peroxisome proliferator-activated receptor-α, -β, and -γ during rat embryonic development. Endocrinology 139(6), 2748-2754 (1998).
34. Huang HE, Chin SR Ginestier C et al. A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene. Cancer Res. 64(19), 6840-6844 (2004).
35. Moskaluk CA, Stoler MH. Agarose mold embedding of cultured cells for tissue microarrays. Diagn. Mol. Pathol. 11(4), 234-238 (2002).
36. Mengel M, Hebel K, Kreipe H, von Wasielewski R. Standardized on-slide control for quality assurance in the immunohistochemical assessment of therapeutic target molecules in breast cancer. Breast J. 11(1), 34-40 (2005).
37. Wynn TA, Thompson RW, Cheever AW, Mentink-Kane MM. Immunopathogenesis of schistosomiasis. Immunol. Rev. 201, 156-167 (2004).
38. Braunschweig D, Simcox T, Samaco RC, LaSalle JM. X-chromosome inactivation ratios affect wild type MeCP2 expression within mosaic Rett syndrome and MeCP2 mouse brain. Hum. Mol. Genet. 13(12), 1275-1286 (2004).
39. Khanna C, Prehn J, Hayden D et al. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin. Cancer Res. 8(7), 2406-2412 (2002).
40. Khanna C, Wan X, Bose S et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nature Med. 10(2), 182-186 (2004).
41. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503-511 (2000).
42. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1), 275-282 (2004).
43. Bova GS, Parmigiani G, Epstein JI et al. Web-based tissue microarray image data analysis: initial validation testing through prostate cancer Gleason grading. Hum. Pathol. 32(4), 417-427 (2001).
44. Shaknovich R, Celestine A, Yang L, Cattoretti G. Novel relational database for tissue microarray analysis. Arch. Pathol. Lab. Med. 127(4), 492-494 (2003).
45. Soenksen DG. Automated microscopic inspection of tissue microarrays using virtual microscopy. American Genomic/Proteomis Technology 28-31 (2003).
46. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. J. Urol. 171(2 Pt 1), 611-614 (2004).
47. Langner C, Lemmerer M, Kornprat P. Analysis of KIT (CD117) expression in gallbladder carcinomas by tissue microarray. Eur. J. Surg. Oncol. 30(8), 847-850 (2004).
48. Shah L, Walter KL, Borczuk AC et al. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 101(7), 1632-1638 (2004).
49. Prall F, Ostwald C, Nizze H, Barten M. Expression profiling of colorectal carcinomas using tissue microarrays: cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis. Appl. Immunohistochem. Mol. Morphol. 12(2), 111-121 (2004).
50. Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 63(4), 651-655 (2004).
51. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res. 63(7), 1445-1448 (2003).
52. Mazal PR, Stichenwirth M, Koller A et al. Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod. Pathol 18(4), 535-540 (2005).
53. Rosell R. Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers. J. Clin. Oncol. 22(7), 1171-1173 (2004).
54. Chang BW, Kim DH, Kowalski DP et al. Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 10(5), 1678-1684 (2004).
55. Choe G, Horvath S, Cloughesy TF et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63(11), 2742-2746 (2003).
56. de Bono JS, Rowinsky EK. Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br. Med. Bull, 64, 227-254 (2002).
57. Rosen DG, Huang X, Deavers MT et al. Validation of tissue microarray technology in ovarian carcinoma. Mod. Pathol. 17(7), 790-797 (2004).
58. Van den Eynden GG, Van der Auwera I, Van Laere S et al. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res. Treat. 85(1), 13-22 (2004).
59. Ginestier C, Charafe-Jauffret E, Penault-Llorca F et al. Comparative multi-methodological measurement of ERBB2 status in breast cancer. J Pathol. 202(3), 286-298 (2004).
60. Gancberg D, Di Leo A, Rouas G et al. Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J. Clin. Pathol. 55(4), 315-317 (2002).
61. Simon R, Nocito A, Hubscher T et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J. Natl Cancer Inst. 93(15), 1141-1146 (2001).
62. Callagy G, Cattaneo E, Daigo Y et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn. Mol. Pathol. 12(1), 27-34 (2003).
63. Ross JS, Fletcher JA, Bloom KJ et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol. Cell Proteomics 3(4), 379-398 (2004).
64. Packeisen J, Buerger H, Krech R, Boecker W. Tissue microarrays: a new approach for quality control in immunohistochemistry. J Clin. Pathol. 55(8), 613-615 (2002).
65. Varma M, Berney DM, Jasani B, Rhodes A. Technical variations in prostatic immunohistochemistry: need for standardisation and stringent quality assurance in PSA and PSAP immunostaining. J Clin. Pathol. 57(7), 687-690 (2004).
66. Diaz LK, Gupta R, Kidwai N, Sneige N, Wiley EL. The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer. J. Histochem. Cytochem. 52(4), 501-507 (2004).
67. Rocchi P, So A, Kojima S et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res. 64(18), 6595-6602 (2004).
68. Bubendorf L, Kolmer M, Kononen J et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J. Natl Cancer Inst. 91(20), 1758-1764 (1999).
69. Lam JS, Belldegrun AS, Figlin RA. Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy. Clin. Cancer Res. 10(18 Pt 2), 6304S-6309S (2004).
70. Kluger HM, Dolled-Filhart M, Rodov S et al. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin. Cancer Res. 10(1 Pt 1), 173-177 (2004).
71. Simpson PT, Gale T, Reis-Filho JS et al. Distribution and significance of 14-3-3σ, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J. Pathol. 202(3), 274-285 (2004).
72. Poremba C, Heine B, Diallo R et al. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J. Pathol. 198(2), 181-189 (2002).
73. Nevalainen MT, Xie J, Torhorst J et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J. Clin. Oncol. 22(11), 2053-2060 (2004).
74. Jirstrom K, Ringberg A, Ferno M, Anagnostaki L, Landberg G. Tissue microarray analyses of G 1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. Br. J. Cancer 89(10), 1920-1926 (2003).
75. Shergill IS, Freeman A, Mundy AR. Tissue microarrays in urology. BJU Int. 94(1), 22-25 (2004).
76. Abd El-Rehim DM, Pinder SE, Paish CE et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 203(2), 661-671 (2004).
77. Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol 95(3), 570-575 (2004).
78. Erez A, Perelman M, Hewitt SM et al. SU overexpression in lung cancer characterizes tumors with increased mitotic activity. Oncogene 23(31), 5371-5377 (2004).
79. Fukuoka J, Fujii T, Shih JH et al. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin. Cancer Res. 10(13), 4314-4324 (2004).
80. Alonso SR, Ortiz P, Pollan M et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am. J. Pathol. 164(1), 193-203 (2004).